AA
MRTX

ALPS Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

ALPS Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-38,235
Closed -$1.42M – 1042
2023
Q1 		$1.42M Sell
38,235
-605
-2% -$27.2K 0.01% 372
2022
Q4 		$1.76M Buy
38,840
+8,461
+28% +$548K 0.02% 318
2022
Q3 		$2.12M Sell
30,379
-2,556
-8% -$189K 0.02% 299
2022
Q2 		$2.21M Buy
+32,935
New +$2.09M 0.02% 304
2020
Q4 		– Sell
-56,836
Closed -$9.44M – 890
2020
Q3 		$9.44M Sell
56,836
-2,694
-5% -$369K 0.14% 136
2020
Q2 		$6.8M Sell
59,530
-17,470
-23% -$1.69M 0.09% 138
2020
Q1 		$5.92M Sell
77,000
-2,456
-3% -$220K 0.09% 134
2019
Q4 		$10.2M Buy
79,456
+1,076
+1% +$104K 0.08% 114
2019
Q3 		$6.11M Buy
78,380
+3,177
+4% +$298K 0.05% 135
2019
Q2 		$7.75M Sell
75,203
-7,231
-9% -$563K 0.06% 130
2019
Q1 		$6.04M Buy
82,434
+7,290
+10% +$496K 0.04% 149
2018
Q4 		$3.19M Buy
75,144
+17,881
+31% +$713K 0.02% 188
2018
Q3 		$2.7M Buy
57,263
+15,104
+36% +$841K 0.02% 216
2018
Q2 		$2.08M Buy
+42,159
New +$1.59M 0.01% 226

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ALPS Advisors's MRTX Position: Q2 2023 in Review

ALPS Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 38,235 shares — an estimated $1.42M sold.

ALPS Advisors first reported a position in MRTX in Q2 2018 and held it in 14 quarters. The position peaked at $10.2M in Q4 2019. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • ALPS Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 38,235 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.42M.
  • ALPS Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 14 quarters.
  • ALPS Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $10.2M in Q4 2019.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.